Revolution Medicines announced that the U.S. Food and Drug Administration has approved its oral tablet daraxonrasib, marketed as Rasonque, for adults with metastatic pancreatic adenocarcinoma (PDAC). The approval follows phase 3 data that showed a 60% reduction in the risk of death compared with standard chemotherapy, extending median overall survival to 13.2 months versus 6.7 months for patients receiving chemotherapy alone.
Pricing and reimbursement landscape
According to a filing with the Securities and Exchange Commission, the drug carries a wholesale acquisition cost of about $39,800 for a 30‑day supply at the recommended daily dose, which translates to roughly $477,000 per year. Trade publication BioPharma Dive noted that this figure is more than double the list price of Merck’s Keytruda, the current top‑selling cancer medication.
Revolution Medicines’ chief financial officer Jack Anders told investors that eligible patients could see the price reduced by 20% to 30% through Medicare Part D and other government discounts. The company’s (ON)Path assistance program is also promoted as a resource to help patients locate financial aid, and the investor call highlighted the possibility of “as little as $0 co‑pay for eligible commercially insured patients.”
Clinical impact and safety profile
The FDA’s decision came 35 days after the agency received Revolution’s application, with regulators describing Rasonque as a “critical new option for patients facing an extraordinarily difficult and historically hard‑to‑treat cancer.” The agency listed the most common adverse events as rash, diarrhea, oral mucositis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.
Anna Berkenblit, M.D., chief scientific and medical officer for the Pancreatic Cancer Action Network, called the approval “the most significant advance we have seen in the fight against pancreatic cancer,” adding that an oral formulation could lessen the burden of intravenous chemotherapy.
Financial considerations for patients
Pancreatic cancer remains the third‑leading cause of cancer death in the United States, with the American Cancer Society projecting about 67,000 new diagnoses in 2026. Because symptoms often appear only after the disease has spread, treatment options are limited and cost concerns are acute.
Most private and government‑sponsored insurance plans cover cancer drugs, but patients should be aware of prior‑authorization requirements and potential out‑of‑pocket costs. For Medicare drug plans, a deductible of up to $615 may apply, followed by a 25% coinsurance until an annual out‑of‑pocket cap of $2,100 is reached. After that threshold, patients enter “catastrophic coverage,” at which point the plan covers 100% of drug costs for the remainder of the year. Low‑income households may qualify for Medicaid coverage of cancer medications and related services.
CancerCare, a nonprofit organization that assists patients with the financial and emotional challenges of cancer, offers a free PDF booklet titled “Managing the Cost of Cancer.” The guide recommends four steps for patients and families: understand health‑insurance terms, keep organized records, log medical expenses, and explore available benefits such as government assistance, veterans’ programs, support groups, or community social‑work services.
While Rasonque’s clinical data represent a notable breakthrough for a disease with historically poor outcomes, its price tag places it among the most expensive oncology therapies on the market. The balance between therapeutic benefit and financial impact will likely shape discussions among providers, insurers, and policymakers as the drug becomes available to patients nationwide.
Mitchell Landsberg is the senior reporter for News Raise and focuses on Technology. Mitchell regularly writes about social media platforms and how influencers, industry and general people use them to communicate and make money.
